For press inquiries click here to contact us.
Relay Therapeutics (Alumni)
Top Story Relay zeroes in on breast cancer subgroup for pivotal PI3Kα inhibitor study
Element Biosciences
How Element Biosciences pushes the boundary of innovation
Avenzo Therapeutics (Alumni)
Exclusive: Athena Countouriotis’ Avenzo taps Shanghai biotech for ADC, adds new funds
Seaport Therapeutics
Seaport Therapeutics adds another $225 million to coffers to embrace the ‘golden age of neuroscience’
Xaira Therapeutics
2024 Nobel Prize in chemistry: Three scientists win for groundbreaking work in proteins
Alumis, Inc. (Alumni)
Promising Long-term Results for ESK-001 in Psoriasis
Xaira Therapeutics
LinkedIn Top Startups 2024: The 50 U.S. companies on the rise
Candid Therapeutics (Alumni)
With $370M debut, Candid Therapeutics is upfront about goal to lead a coming T-cell engager wave
Avenzo Therapeutics (Alumni)
Avenzo and Gilead partner for breast cancer combination regimen trial
Please see important disclaimers in the Terms section.
